U.S. Food and Drug Administration (FDA) officials stated at a recent scientific conference that the science of CBD and other cannabinoids is a priority for the agency.
Dr. Amy Abernethy M.D., Ph.D., Principal Deputy Commissioner of Food and Drugs, and head of the FDA’s CBD Working Group, acknowledged both the the lack of quality science available, and the growing public interest in hemp-derived products.
“We are committed to advancing hemp products with available regulatory pathways, and we are further exploring what additional steps may be appropriate for hemp products, such as those containing CBD, to protect patients and public health, foster innovation for safe products and promote consumer confidence,” she said.
Read the full article at https://hempindustrydaily.com